PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 19151

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR

 

Disease Types: Solid Tumors Research

Eligibility Requirements:

-NSCLC (squamous or non-squamous; mixed histology not allowed) or colorectal solid tumors with KRAS G12c mutations 
-must have unresectable or metastatic disease with no standard of care treatment options available
-NSCLC patients must have had platinum based chemotherapy & treatment with a check point inhibitor 
-no active brain metastasis, carcinomatous meningitis, significant hemoptysis or hemorrhage within last 4 weeks, GI condition or disease that prevents absorption of oral medication, significant heart disease, history of stroke or TIA within last 6 months, or known HIV, active Hep B or Hep C

Available at: